We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Demand for jabs for meningitis, diphtheria and hepatitis recovers after pandemic disruption
US drugmaker expects to deliver 2.1bn doses of the coronavirus shot in 2021
It wants to monetise the trade in iboga, which is reputed to help people kick drug addictions
This scientist’s plague year journal gives fresh insight into the uneasy relationship between science and politics in the UK’s fight to constrain the pandemic
Medical monopolies have allowed inflation to get out of hand, but American politicians are not paying attention
FT analysis finds more than 40 groups including major pharmaceutical companies have accessed patient data sets
State department unveils plan to boost global supplies by spurring creation of overseas factories
Once the world is inoculated, the issue will be one of demand not supply
Latest requirements come as officials struggle to stop spread of Delta variant
German group behind successful Covid jab hopes to have a vaccine in trials by 2022
Dutch group’s shares have plunged since discovery of defective part in its sleep and respiratory devices
Parliament approves watered-down form of contentious bill after marathon weekend debate
Medical adviser Fauci says country ‘going in wrong direction’ as cases rise and jab rate stalls
Anglo-Swedish drugmaker pledges to supply 5m-6m doses as Thailand battles record wave of infections
Despite rising ‘breakthrough infections’ most cases remain mild and are in line with expectations
We need a national conversation about how to share the burden of caring for the old and infirm
New deal for Covid vaccinations comes amid debate over whether Delta variant requires third doses
Strategists say party fears being blamed for surge of infections in red states
Drugs manufacturers say post-Brexit red tape undermines their ability to supply the region
Brian McNamara will run business with annual sales of more than £10bn
Pharma group blames ‘misinformation’ for overshadowing approval of therapy
International Edition